Oddo BHF reiterates its 'outperform' opinion on Moderna, with a price target raised from $118 to $126, 'seeing the clinical, regulatory and commercial risk/reward as positive' for the biotech company specializing in messenger RNA.

In the wake of better-than-expected first-quarter results for 2024, with annual targets confirmed, the research firm is taking the opportunity to marginally adjust its expectations and incorporate the latest market parameters into its price target.

'The next launch will be against respiratory syncitial virus, scheduled for 2024. We believe this launch should reassure investors, who will no longer see Moderna as essentially a Covid 19 player", adds the analyst.

Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.